Treatment selection for recurrent hepatocellular carcinoma (rHCC) after hepatectomy remains challenging. Here, the authors develop HEROVision, a Vision Transformer-based model for personalised prognosis prediction and treatment optimisation in rHCC based on clinical and imaging data, outperforming other guideline staging systems and revealing patients who would benefit from changing treatments.
- Ke Zhang
- Jinyu Ru
- Tianan Jiang
